Zymeworks Inc (OQ:ZYME)

May 31, 2024 07:30 am ET
Zymeworks Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ZYME
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 30, 2024 07:30 am ET
Investors who lost money on Zymeworks Inc. should contact Levi & Korsinsky about an ongoing investigation - ZYME
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 29, 2024 07:30 am ET
Zymeworks Inc. (ZYME) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 28, 2024 07:20 am ET
ATTENTION Zymeworks Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / May 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 28, 2024 06:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will...
May 21, 2024 07:30 am ET
Levi & Korsinsky Reminds Zymeworks Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZYME
NEW YORK, NY / ACCESSWIRE / May 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 19, 2024 10:10 pm ET
Levi & Korsinsky Reminds Zymeworks Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZYME
NEW YORK, NY / ACCESSWIRE / May 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 19, 2024 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zymeworks Inc. (NASDAQ: ZYME), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Jabil Inc. (NYSE: JBL), and DoubleVerify...
May 17, 2024 07:30 am ET
Lost Money on Zymeworks Inc.(ZYME)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / May 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 16, 2024 04:20 pm ET
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Zymeworks Inc. (ZYME)
The law firm of Kirby McInerney LLP reminds investors that the firm is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ:
May 16, 2024 07:25 am ET
Levi & Korsinsky Reminds Zymeworks Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZYME
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 15, 2024 07:35 am ET
Zymeworks Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Zymeworks (ZYME)
NEW YORK, NY / ACCESSWIRE / May 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 14, 2024 07:30 am ET
Levi & Korsinsky Announces an Investigation on Behalf of Zymeworks Inc. (ZYME) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 13, 2024 07:30 am ET
Investors who lost money on Zymeworks Inc. should contact Levi & Korsinsky about an ongoing investigation - ZYME
NEW YORK, NY / ACCESSWIRE / May 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 10, 2024 07:20 am ET
Shareholder Rights Advocates at Levi & Korsinsky Investigate Zymeworks Inc. (ZYME) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / May 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 08, 2024 10:30 pm ET
Shareholders that lost money on Zymeworks Inc.(ZYME) should contact Levi & Korsinsky about Securities Fraud Investigation - ZYME
NEW YORK, NY / ACCESSWIRE / May 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 08, 2024 07:22 am ET
Shareholder Rights Advocates at Levi & Korsinsky Investigate Zymeworks Inc. (ZYME) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / May 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 06, 2024 08:30 pm ET
ATTENTION Zymeworks Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / May 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 06, 2024 07:38 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
NEW YORK, May 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980
May 06, 2024 07:25 am ET
Zymeworks Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - ZYME
NEW YORK, NY / ACCESSWIRE / May 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 02, 2024 09:15 pm ET
Lost Money on Zymeworks Inc.(ZYME)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
May 02, 2024 04:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980 The...
May 02, 2024 04:05 pm ET
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported financial results for the...
May 02, 2024 11:00 am ET
ATTENTION Zymeworks Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
Apr 30, 2024 06:00 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will...
Apr 28, 2024 09:45 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
NEW YORK, April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980
Apr 24, 2024 03:28 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME 
Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980 The...
Apr 20, 2024 12:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
NEW YORK, April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980
Apr 19, 2024 07:25 am ET
ATTENTION ZYME SHAREHOLDERS: Investors who lost money on Zymeworks Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
Apr 18, 2024 07:30 am ET
ZYME ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Zymeworks Inc.
NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
Apr 16, 2024 04:15 pm ET
Levi & Korsinsky Reminds Shareholders of an Investigation into Zymeworks Inc. (ZYME) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
Apr 16, 2024 03:08 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME 
Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980 The...
Apr 12, 2024 10:05 am ET
Zymeworks Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Zymeworks (ZYME)
NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
Apr 12, 2024 10:00 am ET
Levi & Korsinsky Reminds Zymeworks Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZYME
NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
Apr 12, 2024 09:30 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
NEW YORK, April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980
Apr 12, 2024 07:30 am ET
Zymeworks Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ZYME
NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
Apr 11, 2024 06:00 am ET
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will...
Apr 10, 2024 04:45 pm ET
Did Zymeworks Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ZYME
NEW YORK, NY / ACCESSWIRE / April 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
Apr 08, 2024 04:00 pm ET
Zymeworks Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ZYME
NEW YORK, NY / ACCESSWIRE / April 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
Apr 08, 2024 03:08 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980 The...
Apr 08, 2024 06:00 am ET
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced five presentations...
Apr 04, 2024 08:45 pm ET
Zymeworks Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ZYME
NEW YORK, NY / ACCESSWIRE / April 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
Apr 04, 2024 06:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
NEW YORK, April 4, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980
Apr 03, 2024 09:30 pm ET
Zymeworks Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ZYME
NEW YORK, NY / ACCESSWIRE / April 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
Apr 03, 2024 09:00 pm ET
ZYMEWORKS ALERT: Bragar Eagel & Squire, P.C. is Investigating Zymeworks Inc. on Behalf of Zymeworks Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME) on behalf of Zymeworks stockholders. Our investigation concerns...
Apr 03, 2024 08:00 pm ET
Zymeworks Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - ZYME
NEW YORK, NY / ACCESSWIRE / April 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws.
Apr 02, 2024 05:52 pm ET
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)
The law firm of Kirby McInerney LLP is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). The investigation concerns whether Zymeworks and/or certain of its officers have violated the federal...
Apr 01, 2024 05:04 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980 The...
Mar 28, 2024 06:00 am ET
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr....
Mar 27, 2024 06:00 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will...
Mar 06, 2024 04:09 pm ET
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported financial results for the...
Mar 05, 2024 04:30 pm ET
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced acceptance of five...
Feb 27, 2024 06:00 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will...
Feb 14, 2024 06:00 am ET
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will...
Feb 08, 2024 06:00 am ET
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr....
Jan 31, 2024 06:00 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will...
Jan 04, 2024 06:15 am ET
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today provided an update on key strategic...
Jan 04, 2024 06:00 am ET
Zymeworks Announces Additional Leadership Appointments
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced significant additions to...
Dec 26, 2023 08:00 am ET
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today announced that it had entered into a securities purchase agreement with funds affiliated with EcoR1 Capital, LLC...
Dec 15, 2023 08:30 am ET
Zymeworks Added to Nasdaq Biotechnology Index
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Zymeworks’ addition to...
Nov 30, 2023 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conference
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: 42nd Annual J.P. Morgan Healthcare...
Nov 07, 2023 04:05 pm ET
Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the three and nine months ended September 30, 2023 and provided a summary of recent...
Nov 01, 2023 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Jefferies London Healthcare...
Oct 17, 2023 08:30 am ET
Zymeworks To Host Third Quarter 2023 Results Conference Call
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its third quarter 2023 financial results after market close on November 7, 2023....
Oct 16, 2023 04:30 pm ET
Zymeworks Announces New Director Nominee
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today announced that its board of directors will nominate Dr. Nancy Davidson for election to its board of directors at the...
Aug 10, 2023 04:05 pm ET
Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the three and six months ended June 30, 2023 and provided a summary of recent business...
Aug 01, 2023 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Citi's 2023 18th Annual...
Jul 19, 2023 08:30 am ET
Zymeworks To Host Second Quarter 2023 Results Conference Call
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2023 financial results after market close on August 10, 2023....
Jul 03, 2023 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conference
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conference: BTIG Virtual Biotechnology...
Jun 29, 2023 04:05 pm ET
Zymeworks Appoints New Director
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Mr. Carlos E. Campoy to its board of directors effective as of June 30, 2023. Mr. Campoy...
Jun 26, 2023 08:30 am ET
Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that it is set to join both the Russell 3000®, Russell 2000®, and the Russell Microcap® Indexes at the...
Jun 22, 2023 09:31 am ET
Thinking about buying stock in AMC Entertainment, Zymeworks, Tscan Therapeutics, SGHC Ltd, or Workhorse Group?
NEW YORK, June 22, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, ZYME, TCRX, SGHC, and WKHS.
Jun 02, 2023 06:41 pm ET
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate (cORR) of 41.3%, median duration of response (DOR) of 12.9 months, and median progression-free survival (PFS) of 5.5 months (median study follow-up time of 12.4 months)
Jun 01, 2023 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Jefferies Global...
May 18, 2023 08:30 am ET
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the departure of Neil Klompas, President and Chief Operating Officer. Mr. Klompas joined Zymeworks in 2007...
May 08, 2023 04:05 pm ET
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2023 and provided a summary of recent business...
May 01, 2023 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Bank of America Global...
Apr 18, 2023 04:05 pm ET
Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced 11 presentations including new data from its clinical and preclinical development-stage programs at the 2023...
Apr 17, 2023 08:30 am ET
Zymeworks To Host First Quarter 2023 Results Conference Call
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2023 financial results after market close on May 8, 2023. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2023 at 4:30 p.m. Eastern Time (ET).
Apr 10, 2023 08:30 am ET
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023. Mr. Miller brings extensive commercial, corporate and business development, and senior leadership experience in oncology to the Zymeworks board of directors.
Apr 03, 2023 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:
Mar 14, 2023 04:30 pm ET
Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the acceptance of eleven abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the Orange County Convention Center in Orlando, FL from April 14 – 19, 2023.
Mar 07, 2023 04:05 pm ET
Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a summary of recent business highlights.
Feb 28, 2023 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:
Feb 21, 2023 08:30 am ET
Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2022 financial results after market close on March 7th, 2023. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 7th, 2023 at 4:30 p.m. Eastern Standard Time (EST).
Jan 25, 2023 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:
Jan 19, 2023 07:49 am ET
Thinking about buying stock in Zymeworks, CureVac, Apexigen, Gamida Cell, or Xos?
NEW YORK, Jan. 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZYME, CVAC, APGN, GMDA, and XOS.
Jan 19, 2023 06:45 am ET
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease control rate (DCR) of 92%, and median progression-free survival (mPFS) of 12.5 months
Jan 04, 2023 04:15 pm ET
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced updated key strategic priorities and provided updated financial guidance for the 2023 calendar year.
Dec 21, 2022 07:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conference
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:
Dec 21, 2022 06:30 am ET
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers
Dec 19, 2022 07:00 am ET
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology company developing multifunctional biotherapeutics, today announced positive topline results from the pivotal Phase 2b HERIZON-BTC-01 open-label, single-arm clinical trial investigating zanidatamab, a HER2-targeted bispecific antibody, as monotherapy in patients with previously treated HER2-amplified and expressing BTC.
Dec 14, 2022 04:15 pm ET
Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the upcoming presentation of mature Phase 2 data evaluating zanidatamab in combination with chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA) at the ASCO Gastrointestinal Cancers Symposium, taking place in San Francisco, CA and virtually on January 19-21, 2023.
Dec 09, 2022 08:00 am ET
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today presented new clinical data for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor degrader, in patients with heavily pretreated HER2-positive hormone-receptor positive metastatic breast cancer. The data were presented today in a spotlight poster session entitled Treatment of HER2-positive (HER2+) hormone-receptor positive (HR+) metastatic breast
Dec 05, 2022 08:30 am ET
Zymeworks to Transfer Stock Listing to Nasdaq
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that it has elected to transfer its stock exchange listing from the New York Stock Exchange (NYSE) to The Nasdaq Stock Market LLC (Nasdaq), where the vast majority of its biotechnology peer companies also trade.
Nov 29, 2022 08:30 am ET
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, as amended, for
Nov 22, 2022 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conference
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:
Nov 21, 2022 09:00 am ET
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody. Zanidatamab in combination with palbociclib and fulvestrant was well tolerated, with encouraging and durable antitumor activity in heavily pretreated patients with HER2-positive HR+ breast cancer. A poster with an updated and expanded data set will be presented at SABCS taking place in San Antonio, Texas and virtually on December 6-9, 2022.
Nov 08, 2022 04:22 pm ET
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2022.
Oct 20, 2022 08:30 am ET
Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the highlights from its early R&D Day reviewing the Company’s progress and plans for the development of its novel pipeline assets and applications of its proprietary next-generation technology platforms.
Oct 19, 2022 06:07 am ET
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will host a conference call and webcast to discuss Zymeworks has e
Oct 19, 2022 06:00 am ET
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan 
Oct 19, 2022 06:00 am ET
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan 
Oct 18, 2022 08:30 am ET
Zymeworks to Host Third Quarter Results Conference Call
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its third quarter 2022 financial results after market close on November 8th, 2022. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on November 8th, 2022 at 4:30 p.m. ET.
Oct 13, 2022 07:00 am ET
Zymeworks Completes Plan to Become Delaware Corporation
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the completion of its previously announced intention to complete a series of transactions (the “Redomicile Transactions”), resulting in the following: (i) Zymeworks Delaware Inc. (renamed as Zymeworks Inc.) (“New Zymeworks”) becoming the ultimate parent company incorporated in Delaware; (ii) New Zymeworks becoming the direct or indirect owner of all of the assets and liabilities of the former parent company existing under the laws of
Oct 07, 2022 04:15 pm ET
Zymeworks Announces Results of Special Meeting
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce that the Company’s securityholders have approved its plan to become a Delaware corporation (the “Redomicile”) at the special meeting of Zymeworks securityholders (the “Special Meeting”) held in Vancouver, BC, on October 7, 2022.
Oct 04, 2022 08:30 am ET
Zymeworks Reminds Shareholders to Vote FOR its Redomicile
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reminds shareholders that the deadline for voting FOR the Company’s plan to become a Delaware corporation (the “Redomicile”) is 9:00 a.m., Pacific Time, on October 5, 2022. If you require assistance voting your proxy, please contact Kingsdale Advisors at 1-855-476-7981 (within North America), or at 1-416-867-2272 (outside North America), or by email at contactus@kingsdalead
Oct 03, 2022 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences:
Sep 26, 2022 04:15 pm ET
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce that a second independent proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended shareholders vote FOR the Company’s plan to become a Delaware corporation (the “Redomicile”). ISS’ positive recommendation follows
Sep 16, 2022 08:30 am ET
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has recommended that Zymeworks shareholders vote FOR the Company’s plan to become a Delaware corporation (the “Redomicile”).
Sep 12, 2022 04:15 pm ET
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today presented preliminary results from the company’s Phase 1 clinical trial evaluating zanidatamab zovodotin (ZW49) for the treatment of HER2-positive tumors. The presentation, entitled “
Sep 08, 2022 04:15 pm ET
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the proxy statement (“Proxy Statement”) and related materials, dated September 2, 2022 for its special meeting of securityholders (the “Special Meeting”) have been filed publicly and are being mailed to securityholders. The Special Meeting will be held on Friday, October 7, 2022, at 9:00 a.m. Pacific time at the Pearl Room, Fairmont Pacific Rim, 1038 Canada Place, Vancouver, BC V6C 0B9 to approve the previously announced plan to
Sep 04, 2022 06:05 pm ET
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the release of an abstract by ESMO with preliminary results from the company’s Phase 1 study of zanidatamab zovodotin (ZW49), an investigational novel bispecific HER2 targeted antibody-drug conjugate.
Aug 04, 2022 04:15 pm ET
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the second quarter ended June 30, 2022.
Aug 01, 2022 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:
Jul 25, 2022 08:30 am ET
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that data from the company’s Phase 1 study of zanidatamab zovodotin (ZW49), an investigational novel bispecific HER2 targeted antibody-drug conjugate, were accepted for an oral presentation at the European Society for Medical Oncology Congress 2022 in Paris.
Jul 22, 2022 08:30 am ET
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE Rule”), an equity inducement award to Dr. Paul Moore, Zymeworks’ new Chief Scientific Officer.
Jul 21, 2022 08:30 am ET
Zymeworks to Host Second Quarter Results Conference Call
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its second quarter 2022 financial results after market close on August 4th, 2022. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 4th, 2022 at 4:30 p.m. ET.
Jul 15, 2022 08:00 am ET
Zymeworks Announces Plan to Become a Delaware Corporation
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced its intention to become a Delaware corporation (“New Zymeworks”), subject to receipt of necessary shareholder, stock exchange, and court approvals.
Jun 27, 2022 08:30 am ET
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as Chief Scientific Officer, reporting directly to the Chief Executive Officer. Dr. Moore brings more than 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to
Jun 10, 2022 09:15 am ET
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its board of directors (the “Board”) has adopted a limited-duration shareholder rights plan (the “Rights Plan”). The Board adopted the Rights Plan in response to the unsolicited, non-binding proposal by All Blue Falcons FZE (“All Blue”) to acquire Zymeworks and All Blue’s continued share accumulations.
May 27, 2022 08:30 am ET
Thinking about buying stock in Avadel Pharmaceuticals, Solo Brands, Red Robin Gourmet Burgers, DiDi Global, or Zymeworks?
NEW YORK, May 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVDL, DTC, RRGB, DIDI, and ZYME.
May 27, 2022 05:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conference
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:
May 26, 2022 05:00 pm ET
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced new clinical data for the HER2‑targeted bispecific antibody zanidatamab in both HER2-positive breast cancer and gastric/gastroesophageal junction adenocarcinoma. The data are being presented in two separate poster sessions at the American Society of Clinical Oncology (ASCO) Annual Meeting June 3-7, 2022 in Chicago, IL.
May 20, 2022 09:15 am ET
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its Board of Directors, after thorough consultation with its financial and legal advisors, unanimously determined that the unsolicited, opportunistic, non-binding proposal from an activist shareholder, All Blue Falcons FZE (“All Blue”), and its affiliates to purchase Zymeworks for $10.50 per share substantially undervalues Zymeworks and is not in the best interest of the Company and its shareholders.
May 19, 2022 01:00 pm ET
ALL BLUE CAPITAL EXPANDS ITS LEADERSHIP TEAM TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS INC.
Siddhartha Mukherjee, MD, Hematology and Oncology Medical Expert, Rhodes Scholar and Pulitzer Prize Winning Author, Recently Joined All Blue as Medical Advisor
May 04, 2022 04:15 pm ET
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2022.
May 03, 2022 03:27 pm ET
ALL BLUE CAPITAL ANNOUNCES LEADERSHIP TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS, INC.
Alan Barge, MD, Oncology and Biopharmaceutical Drug Development Expert, Former Head of Oncology at AstraZeneca, Recently Joined All Blue as Oncology Drug Development Advisor
May 02, 2022 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:
Apr 29, 2022 08:30 am ET
Thinking about buying stock in Finch Therapeutics, Zymeworks, DiDi Global, Bilibili, or IQIYI?
NEW YORK, April 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FNCH, ZYME, DIDI, BILI, and IQ.
Apr 28, 2022 09:00 pm ET
Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today confirmed it has received an unsolicited, non-binding proposal from All Blue Falcons FZE (“ABF”) and its affiliates to purchase the Company for $10.50 per share in cash.
Apr 28, 2022 08:30 am ET
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it has completed enrollment in its global HERIZON-BTC-01 pivotal clinical trial evaluating the antitumor activity of zanidatamab monotherapy in patients with previously treated advanced or metastatic HER2-amplified biliary tract cancers (BTC), including gallbladder cancer and cholangiocarcinoma (bile duct cancer). Efficacy and safety results from HERIZON-BTC-01 are expected to be announced by early 2023.
Apr 27, 2022 04:15 pm ET
Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced, in conjunction with its Asia Pacific partner BeiGene, the acceptance of two abstracts for poster presentations at the upcoming 2022 ASCO Annual Meeting taking place virtually and in Chicago, IL from June 3 – 7, 2022. The presentations will provide new clinical data from two early-stage studies of zanidatamab in first-line oncology settings.
Apr 19, 2022 04:15 pm ET
Zymeworks to Host First Quarter 2022 Results Conference Call
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its first quarter 2022 financial results after market close on May 4th, 2022. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 4th, 2022 at 4:30 p.m. ET.
Apr 05, 2022 04:01 pm ET
Atreca Announces Expansion of Preclinical Pipeline
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced a...
Apr 01, 2022 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences:
Mar 03, 2022 08:30 am ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences during March:
Feb 24, 2022 04:15 pm ET
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2021 and provided a summary of recent business highlights.
Feb 08, 2022 04:15 pm ET
Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2021 financial results after market close on February 24th, 2022. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on February 24th, 2022 at 4:30 p.m. ET.
Feb 03, 2022 04:15 pm ET
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences.
Jan 31, 2022 12:05 pm ET
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the closing of its previously announced underwritten public offering of 11,035,000 common shares, including the exercise in full of the underwriters’ option to purchase 1,875,000 additional shares, and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,340,000 common shares. The common shares were offered at a public offering price of $8.00 per common share and the pre-funded warrants were offered at a public offering price of
Jan 26, 2022 09:36 pm ET
Zymeworks Announces Pricing of $100.0 Million Public Offering
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the pricing of its underwritten public offering of 9,160,000 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,340,000 common shares. The common shares are being offered at a public offering price of $8.00 per common share and the pre-funded warrants are being offered at a public offering price of $7.9999 per pre-funded warrant, which represents the per share public offering price for each common share less t
Jan 26, 2022 04:01 pm ET
Zymeworks Announces Proposed Public Offering
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. In addition, Zymeworks intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares of
Jan 19, 2022 04:15 pm ET
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today provided a corporate update on its key strategic priorities for 2022 and 2023 in addition to confirming its upcoming clinical development milestones for zanidatamab and ZW49.
Jan 15, 2022 08:30 am ET
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE Rule”), an equity inducement award to Mr. Kenneth Galbraith, Zymeworks’ new Chair, President and Chief Executive Officer.
Jan 10, 2022 06:00 am ET
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2022....
Jan 06, 2022 08:30 am ET
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Klompas, Zymeworks’ Chief Operating Officer and Chief Financial Officer, will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 at 9:45 a.m. ET. The presentation will be webcast live and available for replay on Zymeworks’ website at
Jan 05, 2022 04:30 pm ET
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Mr. Kenneth Galbraith as Chair and Chief Executive Officer (CEO) of Zymeworks, effective on or before February 1, 2022. Mr. Galbraith will succeed Zymeworks co-founder Ali Tehrani, Ph.D., who has served as President and CEO since 2003. Dr. Tehrani will remain as an advisor to the Company to assist with the transition.
Dec 09, 2021 08:30 am ET
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its collaborator, BeiGene, Ltd., has dosed the first patient in South Korea in the HERIZON‑GEA‑01 trial. As a result of this development milestone, Zymeworks will receive a US$8 million payment under its zanidatamab collaboration agreement with BeiGene.
Dec 08, 2021 06:00 pm ET
Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new clinical data for the HER2-targeted bispecific antibody, zanidatamab, in heavily pretreated HER2-positive breast cancer. The data are being presented at the San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas and virtually, December 7-10, 2021. In addition, Zymeworks will present a Trial in Progress poster detailing the ongoing clinical trial evaluating zanidatamab in combination with the CD47-blocker, evorpacept (ALX148).
Dec 01, 2021 08:30 am ET
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Janssen Biotech, Inc. (“Janssen”) dosed the first patient with JNJ-78306358, a bispecific antibody developed using Zymeworks’ Azymetric™ and EFECT™ therapeutic platforms. This is the second Janssen bispecific program utilizing Zymeworks’ proprietary technology platforms to enter the clinic this year, following the announcement in August of Janssen’s dosing of the first patient with JNJ-78278343.
Nov 19, 2021 09:21 am ET
Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody. Zanidatamab in combination with chemotherapy was well tolerated, with encouraging and durable antitumor activity in heavily pretreated patients with HER2-positive breast cancer. A poster with an updated and expanded data set will be presented at SABCS taking place in San Antonio, Texas and virtually on December 7-10, 2021. In addition, Zymeworks will
Nov 09, 2021 04:05 pm ET
Zymeworks Names Neil Josephson, M.D., Chief Medical Officer
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Josephson, M.D., who has been serving as the company’s interim Chief Medical Officer (CMO) since May of this year, will transition to the permanent CMO position, effective November 15.
Nov 09, 2021 08:30 am ET
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced, together with its partner BeiGene, the launch of HERIZON‑GEA‑01. This is a randomized, global Phase 3 study evaluating Zymeworks’ investigational HER2‑targeted bispecific antibody, zanidatamab, plus chemotherapy, with or without BeiGene’s anti-PD‑1‑targeted antibody tislelizumab, versus standard of care (trastuzumab plus chemotherapy), for the first-line treatment of metastatic HER2‑postive GEA.
Nov 08, 2021 04:15 pm ET
Zymeworks to Present at Upcoming Investor Conferences
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming investor conferences.
Nov 03, 2021 04:15 pm ET
Zymeworks Reports 2021 Third Quarter Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2021.
Oct 26, 2021 05:30 am ET
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will host a conference call and webcast to provide details related to the launch of its Phase 3 first-line gastroesophageal adenocarcinoma (GEA) pivotal study, HERIZON-GEA-01, and to discuss the commercial potential of zanidatamab in gastrointestinal cancers.
Oct 05, 2021 08:30 am ET
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumo
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Holdings Inc. (NASDAQ: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in an open-label, multi-center Phase 1b/2 clinical trial conducted by Zymeworks.
Sep 16, 2021 05:30 am ET
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (E
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that new clinical data for zanidatamab, a HER2‑targeted bispecific antibody, demonstrate promising response rates and durability in first-line HER2-positive GEA. These data were presented today by lead study investigator, Geoffrey Ku, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center (MSK), at the ESMO Annual Congress.
Sep 12, 2021 06:49 pm ET
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody, in first-line HER2-expressing GEA. An updated and expanded data set will be presented at the ESMO Annual Congress taking place virtually on September 16-21, 2021.
Aug 04, 2021 04:15 pm ET
Zymeworks Reports 2021 Second Quarter Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the second quarter ended June 30, 2021.
Aug 03, 2021 08:30 am ET
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Janssen Biotech, Inc. (Janssen) dosed the first patient with JNJ-78278343, a bispecific antibody developed using Zymeworks’ Azymetric™ and EFECT™ therapeutic platforms.
Jul 28, 2021 08:30 am ET
Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the first patient has been dosed with zanidatamab in combination with Tukysa® (tucatinib) and capecitabine in a new cohort of a Phase 1 trial for HER2-positive breast cancer patients with locally advanced (unresectable) and/or metastatic disease.
Jul 08, 2021 08:30 am ET
Zymeworks to Present at Ladenburg Thalmann Healthcare Conference
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming Ladenburg Thalmann Healthcare Conference on July 14, 2021 at 4:00 p.m. ET. The presentation will be webcast live and available for replay on Zymeworks’ website at
May 26, 2021 08:30 am ET
Zymeworks to Present at Jefferies Virtual Healthcare Conference
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.
May 06, 2021 08:30 am ET
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
Zymeworks Inc. (NYSE: ZYME), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 5, 2021 (the “Meeting”).
May 05, 2021 04:15 pm ET
Zymeworks Reports 2021 First Quarter Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2021.
Apr 20, 2021 08:45 am ET
Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to its board. New...
Apr 19, 2021 08:30 am ET
Zymeworks Announces Succession Plan for Chief Medical Officer
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Diana Hausman, M.D., will be transitioning out of her role as Zymeworks’ Chief Medical Officer (CMO) and assuming an executive advisory role until November 15th, 2021. Neil Josephson, M.D., who currently oversees Zymeworks’ global clinical studies in his role as Senior Vice President, Clinical Research, will assume the role of interim CMO.
Apr 13, 2021 08:30 am ET
Zymeworks to Present at Bloom Burton Healthcare Conference
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming 2021 Bloom Burton Healthcare Investor Conference taking place April 20-21, 2021.
Apr 10, 2021 08:30 am ET
Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced five presentations at the American Association for Cancer Research (AACR) Annual Meeting. The presentations highlight preclinical data that reveal new insights into the unique mechanisms of action of lead clinical candidate, zanidatamab, introduce Zymeworks’ fourth therapeutic platform, ProTECT™, and describe two new preclinical assets focused on the cytokine, IL-12, and the immune-oncology target, 4-1BB.
Mar 10, 2021 05:27 pm ET
Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the acceptance of five abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 taking place virtually from April 10 – 15, 2021.
Feb 24, 2021 04:15 pm ET
Zymeworks Reports 2020 Year-End Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2020 and provided a summary of recent business and clinical highlights.
Feb 10, 2021 04:15 pm ET
Zymeworks to Participate in Upcoming Investor Conferences and Events
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that management will participate in five upcoming virtual investor conferences.
Feb 09, 2021 04:30 pm ET
Zymeworks Expands Commercial Team and Creates New R&D Role
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that James Priour, former Senior Vice President, Commercial, has been promoted to Chief Commercial Officer and named to the Company’s Executive Committee. The Commercial team also recently expanded its leadership with the addition of Manny Duenas as Vice President, Global Value & Access. Zymeworks also announced that John Babcook, former head of Discovery Research, will move into a newly created Distinguished Fellow role. Senior Vice President of Research Guowei F
Jan 27, 2021 05:15 pm ET
Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that the Company has begun enrolling patients into the expansion cohort portion of the ongoing Phase 1 clinical trial for ZW49, its novel HER2-targeted antibody-drug conjugate (ADC). Supporting data from the Phase 1 dose escalation portion were highlighted today via a webcast and conference call and are summarized below.
Jan 15, 2021 08:30 am ET
Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new and updated clinical data for the HER2‑targeted bispecific antibody zanidatamab, in both HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA). The data are being presented today at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually January 15 – 17, 2021.
Jan 11, 2021 08:00 am ET
Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2020 and updated its corporate priorities.
Jan 07, 2021 08:30 am ET
Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 39th Annual J.P. Morgan Healthcare Conference. In addition, Zymeworks will host two webcasts in January to discuss the zanidatamab clinical data presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) and provide an update on ZW49’s clinical progress.
Dec 10, 2020 08:30 am ET
Zanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the selection of three abstracts for presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually on January 15 – 17, 2021.
Dec 02, 2020 08:00 am ET
Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
Exelixis, Inc. (Nasdaq: EXEL), Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. (NYSE:ZYME) today announced that Exelixis has exercised its exclusive option for Iconic’s lead oncology antibody-drug conjugate (ADC) program under the companies’ May 2019
Dec 01, 2020 08:30 am ET
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration With BeiGene
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in South Korea in a pivotal, single-arm clinical trial of zanidatamab (formerly ZW25) monotherapy in patients with advanced or metastatic HER2-amplified biliary tract cancer (BTC). Zymeworks will receive a US$10 million payment under its collaboration with BeiGene as a result of the achievement of this development milestone.
Nov 30, 2020 08:30 am ET
Zymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for zanidatamab in patients with previously-treated HER2 gene-amplified biliary tract cancer (BTC).
Nov 19, 2020 08:30 am ET
Zymeworks Receives Orphan Drug Designation From the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients With Gastric Cancer
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the European Commission (EC) has granted Orphan Drug designation for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in patients with gastric cancer.
Nov 16, 2020 04:15 pm ET
Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Holdings Inc. (NASDAQ: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced they have entered into a clinical collaboration to evaluate the combination of Zymeworks’ zanidatamab (formerly ZW25), a HER2-targeted bispecific antibody, and ALX148, a next-generation CD47 blocker, for the treatment of patients with advanced HER2-expressing breast cancer and other solid tumors.
Nov 10, 2020 08:30 am ET
Zymeworks to Present at Upcoming Investor Conferences
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in four upcoming virtual investor conferences.
Nov 03, 2020 04:15 pm ET
Zymeworks Reports 2020 Third Quarter Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the quarter ended September 30, 2020.
Sep 03, 2020 08:30 am ET
Zymeworks to Present at Upcoming Investor Conferences
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming virtual investor conferences.
Aug 05, 2020 04:15 pm ET
Zymeworks Reports 2020 Second Quarter Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the quarter ended June 30, 2020.
Jul 08, 2020 05:30 pm ET
Zymeworks Corporate Update Webcast and Conference Call Summary
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today hosted a webcast and conference call highlighting its progress and key accomplishments in the first half of 2020.
Jul 08, 2020 04:15 pm ET
Zymeworks Announces New Multispecific Antibody Collaboration with Merck
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longtime partner, Merck (known as MSD outside the US and Canada) have signed a new license agreement granting Merck the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric™ and EFECT™ platforms.
Jun 30, 2020 08:30 am ET
Zymeworks Announces Corporate Update Webcast and Conference Call
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that it will host a webcast and conference call to discuss progress on its corporate priorities and upcoming catalysts.
May 28, 2020 08:30 am ET
Zymeworks to Present at the Jefferies 2020 Virtual Healthcare Conference
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Jefferies 2020 Virtual Healthcare Conference taking place June 2-4, 2020.
May 08, 2020 08:30 am ET
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 7, 2020 (the “Meeting”).
May 07, 2020 04:15 pm ET
Zymeworks Reports 2020 First Quarter Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2020.
Apr 01, 2020 04:15 pm ET
Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in a two-arm Phase 1b/2 trial evaluating Zymeworks’ HER2-targeted bispecific antibody ZW25 in combination with chemotherapy as a first-line treatment for patients with metastatic HER2-positive breast cancer and in combination with chemotherapy and BeiGene’s PD-1-targeted antibody tislelizumab as a first-line treatment for patients with metastatic HER2-positive gastroesophageal adenocarcinoma (GEA). Zymew
Mar 16, 2020 06:50 am ET
Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Kelvin Neu, M.D., to its Board of Directors.
Mar 02, 2020 04:15 pm ET
 Zymeworks Reports 2019 Year-End Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2019.
Feb 24, 2020 08:30 am ET
Zymeworks to Present at Raymond James 41st Annual Institutional Investors Conference
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Raymond James Institutional Investors Conference taking place March 1-4, 2020 in Orlando, FL.
Jan 27, 2020 09:45 am ET
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Over-Allotment Option to Purchase Additional Shares
Zymeworks Inc. (NYSE: ZYME), a clinical stage biopharmaceutical company developing multifunctional biotherapeutics (“Zymeworks” or the “Company”), announced today the closing of its previously announced underwritten public offering (the “Offering”). The Offering consisted of 5,824,729 common shares, including the exercise in full of the underwriters’ over-allotment option to purchase 900,000 additional shares, and, in lieu of common shares, to a certain investor, pre-funded warrants to purchase up to 1,075,271 common shares. The common shares were offered at

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.